Foghorn Therapeutics Inc. (FHTX)

5.56 -0.38 (-6.40%) At close: 04:00PM EDT

Foghorn Therapeutics Inc.

500 Technology Square
Suite 700
Cambridge, MA 02139
United States
617 586 3100
https://foghorntx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 116

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Adrian H. B. Gottschalk	President, CEO & Director	784.65k	N/A	1976
Dr. Steven F. Bellon Ph.D.	Chief Scientific Officer	572.6k	N/A	1965
Dr. Alfonso Quintas Cardama M.D.	Chief Medical Officer	300.16k	N/A	1971
Dr. Gerald R. Crabtree M.d.	Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Kristian Humer M.B.A.	Chief Financial Officer	N/A	N/A	1976
Ms. Karin Hellsvik	VP, Corporate Affairs & Investor Relations	N/A	N/A	N/A
Mr. Michael J. LaCascia	Chief Legal Officer	565.5k	N/A	1965
Mr. Saurabh Sewak Ph.D.	Vice President of Corporate Development	N/A	N/A	N/A
Mr. Carlos Costa	Chief People Officer	N/A	N/A	1973
Ms. Fanny Cavalie	Chief Strategy & Business Operations Officer	N/A	N/A	1978

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Foghorn Therapeutics Inc.’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 4; Board: 7; Shareholder rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.